Core Viewpoint - China Antibody-B (03681) has seen a significant increase in stock price, rising over 5% and reaching HKD 2.04, with a trading volume of HKD 13.36 million, following the publication of its preclinical study on the novel anti-IL-17RB antibody SM17 in a European respiratory journal [1] Group 1 - The preclinical study of SM17 demonstrates its potential to significantly improve the pathological features of chronic rhinosinusitis with nasal polyps (CRSwNP) and idiopathic pulmonary fibrosis (IPF) through dual inhibition of the Th2/Th17 pathways and antifibrotic activity [1] - The Chairman and CEO of China Antibody expressed excitement over the publication, highlighting SM17's potential as a groundbreaking therapy for CRSwNP and IPF [1] - SM17 targets key upstream alarmin IL-25 and may provide a multifaceted treatment strategy for CRSwNP and IPF by simultaneously addressing Th2 inflammation, Th17 differentiation, and fibrosis, potentially filling the unmet needs in current downstream effector therapies [1]

Core Viewpoint - The release of the China-themed special issue of "Allergy" highlights significant advancements in the treatment of allergic diseases through biologics, showcasing the contributions of Chinese scholars to the global allergy science community [1][2]. Group 1: Publication and Impact - The special issue features 32 articles authored by Chinese scholars, focusing on various fields including allergy science, rhinology, respiratory medicine, and dermatology [1]. - "Allergy," established in 1948, has an impact factor of 12.6 in 2023, making it one of the most prestigious journals in the field of allergy science and clinical immunology [1]. - The editor-in-chief, Cezmi Akdis, praised the academic achievements of Chinese scholars, noting their positive influence on the global allergy science field [1]. Group 2: Advances in Treatment - Biologics are identified as a promising direction for treating allergic diseases, with increasing clinical experience expected to benefit more patients with difficult-to-treat and severe conditions [2]. - A Chinese consensus document on the use of biologics for chronic rhinosinusitis with nasal polyps was published, providing authoritative guidance on patient selection, treatment protocols, and efficacy evaluation [2]. - The special issue also includes research on the mechanisms of asthma related to environmental pollution, gut microbiome dysbiosis, and drug allergies, contributing innovative insights to the global allergy discipline [2].